戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 sociated with reduced expression of vascular endothelin.
2 ects of another GWAS signal were mediated by endothelin.
3  (LPA; acting through the LPA1 receptor) and endothelin.
4 orsal Jag1 expression but also by inhibiting endothelin 1 (Edn1) expression in the pharyngeal endoder
5 perturbations demonstrates complex roles for Endothelin 1 (Edn1) signaling in the intermediate joint-
6 emonstrate rs9349379 regulates expression of endothelin 1 (EDN1), a gene located 600 kb upstream of P
7 etermine the selective affinity of EDNRA for endothelin 1 (EDN1), its major physiological ligand, and
8 ular density) and the potent vasoconstrictor endothelin 1 (EDN1); we assayed the activity of angioten
9                                              Endothelin 1 (ET-1) and ET-2 activate two G protein-coup
10                                              Endothelin 1 (ET-1), mainly produced from vascular endot
11 mpaired vasodilator reactivity and increased endothelin 1 (ET-1)-mediated vasoconstriction, two abnor
12 eased expression of vasoconstrictor molecule endothelin 1 and a concomitant decrease in vasodilatory
13 scription by Dot1a and HDAC2, and reinforces endothelin 1 as a therapeutic target of kidney fibrosis.
14 lly polarized molecular landscape identified endothelin 1 as an important secreted regulator of human
15 tic effect by repressing Edn1, which encodes endothelin 1 in the connecting tubule/collecting duct.
16 e complement anaphylatoxins C3a and C5a, and endothelin 1, induced human MCs rapidly to secrete small
17 atory BP), arterial stiffness, nitric oxide, endothelin 1, or blood lipid profile.
18 resence of an endothelin-converting enzyme 1/endothelin 1-SphK positive feedback loop.
19 er quartile); pulmonary hypertension and low endothelin-1 <1.7 pg/mL; lower 3 quartiles); no pulmonar
20 ould be explained by an enhanced response to endothelin-1 (20% greater reduction in lumen diameter, P
21 locus acting as a potential enhancer for the endothelin-1 (EDN1) gene.
22 d cardiovascular progenitors using WNT3A and endothelin-1 (EDN1) human recombinant proteins.
23 s the secretion of a potent vasoconstrictor, endothelin-1 (EDN1), which continues to increase as the
24 (Ednra) expression and increased circulating endothelin-1 (Edn1).
25 NGF, miR-98, PPARgamma, fibronectin 1 (FN1), endothelin-1 (EDN1, herein referred to as ET-1), and col
26  oxygen species, which evoked the release of endothelin-1 (ET) that activated pericyte ET(A) receptor
27 teral striatal injection of vasoconstrictive endothelin-1 (ET-1) along with Abeta toxicity on CNS pat
28 newborn arteries also expresses and releases endothelin-1 (ET-1) and initiates endothelium-dependent
29                                              Endothelin-1 (ET-1) antagonists are a possibility becaus
30         Gene profiling identified inter alia endothelin-1 (ET-1) as one of the target genes of P2Y4 i
31                Previous studies suggest that endothelin-1 (ET-1) contributes to the pathogenesis of E
32                                              Endothelin-1 (ET-1) dose and time-dependently up-regulat
33 (NGAL), kidney injury molecule-1 (KIM-1) and endothelin-1 (ET-1) during EVKP in a series of discarded
34    Endothelial expression and the release of endothelin-1 (ET-1) in levels sufficient to initiate vas
35                                              Endothelin-1 (ET-1) is a potent endothelial-derived vaso
36                  The vasoconstrictor peptide endothelin-1 (ET-1) is a transcriptional target of TGF-b
37                                              Endothelin-1 (ET-1) is a vasoactive peptide that is elev
38                                              Endothelin-1 (ET-1) is an indicator of endothelial injur
39                                        Since endothelin-1 (ET-1) is implicated in blood pressure (BP)
40 ceptor mediating the vasodilatory effects of endothelin-1 (ET-1) is induced by OA-NO2 Inasmuch as ET-
41                                              Endothelin-1 (ET-1) is involved in the pathogenesis of c
42 rum concentrations of the vasoactive protein endothelin-1 (ET-1) occur in the setting of systemic inf
43 The present study investigated the effect of endothelin-1 (ET-1) on cholinergic mechanisms of end-org
44 y increasing nitric oxide and downregulating endothelin-1 (ET-1) production, has been implicated in I
45                                              Endothelin-1 (ET-1) promotes renal damage during cardiov
46 s including angiotensin II, aldosterone, and endothelin-1 (ET-1) that mediate the immediate benefit o
47  increased expression of the vasoconstrictor endothelin-1 (ET-1) within PASMCs.
48                         Here, we report that Endothelin-1 (ET-1), a molecular component of the postna
49 ) correlated with increased plasma levels of endothelin-1 (ET-1), a potent vasoconstrictor, in sickle
50 xpression of the endothelin axis components [endothelin-1 (ET-1), endothelin-3 (ET-3), endothelin rec
51                  Vasoconstrictors, including endothelin-1 (ET-1), inhibit myocyte BK channels, leadin
52 trictions of venules from euglycemic pigs to endothelin-1 (ET-1), thromboxane analog U46619, and nore
53                                              Endothelin-1 (ET1) synthesis is understood to promote ca
54                         We hypothesized that endothelin-1 (ET1), a secreted paracrine factor of ECs,
55 ubgroup with pulmonary hypertension and high endothelin-1 (high endothelin-1: >/=1.7 pg/mL; upper qua
56 lin-1; and no pulmonary hypertension and low endothelin-1 (log-rank chi2 = 77.16; P < .01 ).
57  these proteins in DN, and demonstrated that endothelin-1 activates podocytes to release heparanase.
58                                              Endothelin-1 activates the phospholipase C pathway, lead
59            The endothelial specific mediator endothelin-1 along with interleukin (IL)-6, IL-8, tumor
60 of ARHGAP18 resulted in a failure to secrete endothelin-1 and a reduction in neutrophil transmigratio
61 (OPN) in mouse arteries via local release of endothelin-1 and activation of CREB.
62 y PGP levels associate with both circulating endothelin-1 and acute rejection in cardiac transplant p
63 nterleukin-6 and osteopontin, lowered plasma endothelin-1 and blood pressure, and improved mouse surv
64 eraction with GRK2 is inversely regulated by endothelin-1 and CAV1 scaffolding domain after liver inj
65 lacylcarnitines correlated with increases in endothelin-1 and creatinine/cystatin C, respectively.
66 -beta1 signaling and increased expression of endothelin-1 and genes involved in VSMC contraction, hig
67                                     However, endothelin-1 and IL-6 increased, and IL-10 decreased, be
68 ibited lower oxidative stress, expression of endothelin-1 and monocyte chemoattractant protein-1, and
69                                       Plasma endothelin-1 and OPN concentrations are positively corre
70     Despite pathophysiological links between endothelin-1 and pulmonary vascular remodeling, to our k
71 e previously showed that both heparanase and endothelin-1 are essential for the development of DN.
72 es of evidence have demonstrated the role of endothelin-1 as both a constrictor of uterine myometrial
73                             In injured SECs, endothelin-1 blocked CAV1 phosphorylation induced by CAV
74 y in systemic sclerosis after macitentan, an endothelin-1 blocker.
75 emokine Receptor 2 (CXCR2) and production of endothelin-1 both in vitro and in vivo.
76 a) and the neuroendocrine regulatory peptide endothelin-1 by DH82 cells.
77  fumigatus specifically caused production of endothelin-1 by epithelial cells in vitro but not any of
78                                Also, whether endothelin-1 can predict future heart failure and mortal
79 lymphopoietin-induced Ca(2+)-influx, whereas endothelin-1 caused itch-selective B-type natriuretic pe
80 tic peptide), and cGMP, and decreased plasma endothelin-1 compared with PH alone.
81  TGFbeta1 signaling via type I receptors and endothelin-1 contribute to mesenchymal lineage transitio
82                                              Endothelin-1 differentially directs lineage specificatio
83 ist, we demonstrated for the first time that endothelin-1 drives many features of airway remodelling
84 GFR, plasma renin concentration, and urinary endothelin-1 excretion were similar between knockout and
85       Mediation analysis showed that BNP and endothelin-1 explained 56% and 40%, respectively, of the
86 = 0.0009) expression, with no differences in endothelin-1 expression.
87 EndMT, suppression of eNOS, and induction of endothelin-1 expression.
88  fibroblasts were treated with 20 and 100 nM endothelin-1 for 6 and 24 hours and then collected to as
89 dney vasculature and normalized Tgf-beta and endothelin-1 gene expression in aged MWF rats.
90 array analysis showed increased Tgf-beta and endothelin-1 gene expression with age.
91 generated low-expressing and high-expressing endothelin-1 genes (L and H) and have bred mice with fou
92                     A fumigatus also induced endothelin-1 in murine lungs, associated with extensive
93          Accordingly, VAMP3 co-occurred with endothelin-1 in the skins of patients with AD.
94 the expression of contractile markers and of endothelin-1 in VSMCs.
95 s not known whether elevated serum levels of endothelin-1 indicate future risk of kidney disease in t
96 s on d1, d7, and d28 post Abeta toxicity and endothelin-1 induced ischemia (ET1) in rats.
97                                Specifically, endothelin-1 induces sympathetic neurons expressing the
98           Vasoconstriction blockade with the endothelin-1 inhibitor BQ-123, or ROS scavenging after S
99                             We conclude that endothelin-1 is critical for maintaining normal contract
100  0.05), but not in vascular endothelial cell endothelin-1 knockout (VEET KO) mice (76.4 +/- 5.7 pg/mg
101 ular risk in black adults, we measured serum endothelin-1 level at baseline (2000-2004; n=3538).
102    Phenotyping by pulmonary hypertension and endothelin-1 level showed mortality decreasing in order
103                       Log-transformed plasma endothelin-1 level.
104 ur knowledge, the association between plasma endothelin-1 levels and pulmonary hypertension has not b
105 ied African American individuals with plasma endothelin-1 levels and tricuspid regurgitation on echoc
106         In conclusion, higher baseline serum endothelin-1 levels associated with incident CKD and all
107 consistent with the hypothesis that elevated endothelin-1 levels contribute to subepithelial thickeni
108                   Participants with baseline endothelin-1 levels in higher quartiles had a greater in
109                                    Mean (SD) endothelin-1 levels were 1.36 (0.64) pg/mL; 217 of 3223
110 g for potential confounders, log-transformed endothelin-1 levels were associated with increased odds
111                              Log-transformed endothelin-1 levels were associated with mortality (adju
112                   Mechanistically, increased endothelin-1 levels were detected in TGFbetaRII-KO endot
113                                              Endothelin-1 levels were significantly increased 20 hr a
114                              Elevated plasma endothelin-1 levels, especially associated with an eleva
115 tion of the endothelin-A receptor (EDNRA) by endothelin-1 may play a role in the disease because the
116 antinociceptive effect through inhibition of endothelin-1 mediated neuronal activation, revealing the
117  specimens and plasma of CTEPH patients, and endothelin-1 overexpression was prevented by inhibition
118 rease in eNOS expression, and an increase in endothelin-1 plasma levels, with all mice dying within 5
119                                              Endothelin-1 positively associated with all-cause mortal
120                                              Endothelin-1 promotes vasculopathy in systemic sclerosis
121                            Using a selective endothelin-1 receptor antagonist, we demonstrated for th
122 ion was associated with increased glomerular endothelin-1 receptor type A (Ednra) expression and incr
123 esting that p66Shc expression did not affect endothelin-1 release from resident endothelial cells.
124                         Acute application of endothelin-1 revealed significantly elevated production
125        Of these, the vasoconstrictive factor endothelin-1 serves as an integral point of communicatio
126           Our data suggest that in diabetes, endothelin-1 signaling, as occurs in endothelial activat
127                                              Endothelin-1 stimulated the production of MMP1, MMP8, an
128 cell Abs-angiotensin type 1 receptor (AT1R), endothelin-1 type A and natural polyreactive Abs-did not
129 anti-angiotensin II type-1 receptor and anti-endothelin-1 type A receptor autoantibodies are associat
130 tatus for angiotensin II type-1 receptor and endothelin-1 type A receptor autoantibodies pre-LT, and
131 PKG) activity independently of diet, whereas endothelin-1 was increased by diet and Abeta42.
132           The extracellular concentration of endothelin-1 was increased following GLO1-knockdown, whe
133 illations triggered by endogenously released endothelin-1 were recorded in smooth muscle cells of the
134                           The levels of ET-1(endothelin-1) and Ang II (Angiotensin II) in the plasma
135  levels of the vasoconstrictor peptide ET-1 (endothelin-1) and higher levels of the 2 potent vasodila
136 ious pruritogens (histamine, chloroquine, or endothelin-1) and recorded spontaneous scratching before
137 to histaminergic (histamine, compound 48/80, endothelin-1), not non-histaminergic (chloroquine) pruri
138 ure to vasoconstrictors (50 mM KCl and 20 nM Endothelin-1).
139 creased production of vasoconstrictors (e.g. endothelin-1).
140  (adjusted hazard ratio per log increment in endothelin-1, 1.57, 95% CI, 1.05-2.37; median follow-up,
141 on (adjusted odds ratio per log increment in endothelin-1, 1.66; 95% CI, 1.16-2.37).
142  (adjusted hazard ratio per log increment in endothelin-1, 1.69; 95% CI, 1.27-2.25; median follow-up,
143                                              Endothelin-1, a marker of endothelial dysfunction, is a
144                                              Endothelin-1, a very potent vasoconstrictor, is a key mo
145                      We assessed the role of endothelin-1, acting through endothelin A (ET(A) ) recep
146  uremic toxins (i.e., uric acid, phosphates, endothelin-1, advanced glycation end-products, and asymm
147 (ICAM-1), anti-LG3, aminopeptidase N, CXCL9, endothelin-1, and gelsolin.
148 ated cytokines thymic stromal lymphopoietin, endothelin-1, and inflammatory tumor necrosis factor-alp
149 transforming growth factor beta1 (TGFbeta1), endothelin-1, and NAD(P)H oxidase 4 also occur in parall
150 k involving transforming growth factor-beta, endothelin-1, angiotensin II, CCN2 (connective tissue gr
151 ate that BMP9 can affect the balance between endothelin-1, apelin, and adrenomedullin.
152 factors, TGF-beta1, TGF-beta2, periostin and endothelin-1, by human airway epithelial cells and in mi
153 procalcitonin, MR-pro-adrenomedullin, CT-pro-endothelin-1, CT-pro-arginine vasopressin, and MR-pro-at
154 hic acid I, calcitonin gene-related peptide, endothelin-1, gentamicin, norepinephrine and vasopressin
155 othelin-1; (d) immunohistochemistry of eNOS, endothelin-1, P-selectin, intercellular adhesion molecul
156 with elevated vasoconstrictor signalling via endothelin-1, reduces the local vasodilatory response to
157 activated gene networks involved in calcium, endothelin-1, renin-angiotensin, and cardiac beta-adrene
158 cterised by the measurement of nitric oxide, endothelin-1, tissue plasminogen activator and plasminog
159 s elicited by phenylephrine, angiotensin II, endothelin-1, U46619, and K(+)-induced membrane depolari
160 es was increased expression and secretion of endothelin-1, which is also a known pruritogen.
161                                    In vitro, endothelin-1- and, in vivo, pressure overload-induced ca
162                                          The endothelin-1-induced vasodilation in these PCOS subject,
163 zed mesenteric arteries pre-constricted with endothelin-1.
164 cluding BNP (B-type natriuretic peptide) and endothelin-1.
165 t in the eNOS/cGMP/PKG pathway and decreased endothelin-1.
166 e including thymic stromal lymphopoietin and endothelin-1.
167 els mediate their spontaneous motion via the endothelin-1/endothelin receptor A pathway.
168 ary hypertension and high endothelin-1 (high endothelin-1: >/=1.7 pg/mL; upper quartile); pulmonary h
169 endothelial nitric oxide synthase (eNOS) and endothelin-1; (d) immunohistochemistry of eNOS, endothel
170 artiles); no pulmonary hypertension and high endothelin-1; and no pulmonary hypertension and low endo
171 ise in the expression of the vasoconstrictor endothelin 2 by follicle cells of wild-type mice.
172 e mice, infusion of vasoconstrictors (either endothelin 2 or angiotensin 2) into the bursa restored t
173  Although increasing evidence indicates that endothelin-2 (Edn2) has distinct roles in tissue patholo
174                                              Endothelin-2 (EDN2) is a potent vasoconstrictor that is
175 in white mutants a transcriptional defect in endothelin 3 (edn3), encoding a peptide factor that prom
176 d by molecules such as the signaling protein endothelin 3 (EDN3), its receptor (the endothelin recept
177 thelin axis components [endothelin-1 (ET-1), endothelin-3 (ET-3), endothelin receptor A (EdnrA), Ednr
178  comprehensive panel of pruritogens (C48/80, endothelin, 5-HT, chloroquine, histamine, lysophosphatid
179 sed the role of endothelin-1, acting through endothelin A (ET(A) ) receptors, in modulating the centr
180 in axis, which is a pathway comprised of the endothelin A and B receptors (ET(A)R and ET(B)R).
181                             Mechanistically, endothelin A receptor (ETAR)-positive macrophages are hi
182 2 diabetes using a low dose of the selective endothelin A receptor antagonist atrasentan reduces albu
183                      Atrasentan, a selective endothelin A receptor antagonist, has been shown to redu
184 ion of similar magnitude (P </= 0.05) of the endothelin A receptor in the lung tissue.
185 dothelin signaling via the activation of the endothelin-A receptor (EDNRA) by endothelin-1 may play a
186 o three groups: placebo (RVD+PTRAS), chronic endothelin-A receptor (ET-A) blockade (RVD+PTRAS+ET-A),
187 g-term treatment strategy with the selective endothelin-A receptor (ETA) antagonist, ambrisentan, des
188 pressure, augmentation index, blood glucose, endothelin, adhesion molecules, or clotting factors in t
189 ggered by two keratinocyte-secreted factors, endothelin and acetylcholine, which acted via specific m
190                              While targeting endothelin and angiotensin, which are upstream regulator
191  indicating that Six1 and Six2 regulate both endothelin and bone morphogenetic protein-4 signaling pa
192 factor, vascular endothelial growth factor), endothelin and inhibitors of chemotaxis.
193 n various mediators, including nitric oxide, endothelin, and prostanoids, among others.
194 oncentration of catecholamines, vasopressin, endothelin, and renin activity in 14 patients with CIPA,
195                                          The endothelin axis and in particular the two endothelin rec
196                                     We found endothelin axis component (EdnrA, EdnrB, ET-1, ET-3) exp
197                            Expression of the endothelin axis components [endothelin-1 (ET-1), endothe
198 genes of the pathway, demonstrating that the endothelin axis genes are methylated and dysregulated in
199 er metastasis and pain are controlled by the endothelin axis, which is a pathway comprised of the end
200                                          The endothelin B receptor (ET(B) R) subtype mediates vasodil
201  to a cysteine sulfenic acid modification in endothelin B receptor and consequently decreased endothe
202 BR-4628 against IR was lost when a selective endothelin B receptor antagonist was coadministered.
203                We have demonstrated cerebral endothelin B receptors (ETBR) as a potential target to t
204                                              Endothelin-B receptor agonist, IRL-1620, provides signif
205                                          The endothelins comprise three structurally similar peptides
206 a nicotinic receptor (CHRNG, 6 subjects) and endothelin converting enzyme-like 1 (ECEL1, 4 subjects).
207                  Metalloproteases, including endothelin-converting enzyme (ECE)-1 and -2, reside with
208 nists (BQ123 plus BQ788) or by inhibition of endothelin-converting enzyme (phosphoramidon or SM19712)
209 empty spiracles homeobox 1 [EMX1], AK055957, endothelin-converting enzyme 1 [ECE1], phosphofructokina
210 -1 expression, indicating the presence of an endothelin-converting enzyme 1/endothelin 1-SphK positiv
211 t inhibition of SphK leads to suppression of endothelin-converting enzyme-1 expression, indicating th
212                      We further identify the endothelin/Ednra pathway as an autocrine activator of Gq
213  receptors (GPCRs), including adrenergic and endothelin (ET) receptors, after elevated neurohormonal
214                                        While endothelin (ET)-1 plays a role in regulating blood flow
215 layed a vasoconstriction response to KCl and endothelin for each experimental group.
216 osis factor-alpha, IL-1b, troponin, vascular endothelin growth factor, IL-17a, matrix metallopeptidas
217                                              Endothelin-induced vasoconstriction by hepatic stellate
218 C-dependent, positive-feedback mechanism for Endothelin induction and establish MEF2C as an immediate
219 est enhancer from the mouse genome abolishes Endothelin induction of Mef2c expression.
220 dies have identified important roles for the endothelin isoforms and new therapeutic targets during d
221 ity associated with experience by regulating endothelin levels, which in turn affect the myelinating
222                                              Endothelin ligands (Edns) and endothelin receptors (Ednr
223 alyzed the expression of the complete set of endothelin ligands and receptors in the jawless vertebra
224 S/MS to identify NT-proET-1 (ppET-1[18-50]), Endothelin-Like Domain Peptide (ELDP, ppET-1[93-166]) an
225     ELDP contains the evolutionary conserved endothelin-like domain sequence, which potentially confe
226                      Further, normal Wnt and Endothelin niche signals during hair anagen onset are hi
227                            In the absence of endothelin or plexin signaling, sympathetic neurons misp
228 pressure, augmentation index, blood glucose, endothelin, proprotein convertase subtilisin/kexin type
229 y by Jagged-Notch signaling and ventrally by endothelin receptor A (EDNRA) signaling.
230 s [endothelin-1 (ET-1), endothelin-3 (ET-3), endothelin receptor A (EdnrA), EdnrB] were determined ov
231 reast cancer cells through interference with endothelin receptor A (ETA).
232                                              Endothelin receptor A and p66Shc regulate spontaneous Ca
233 ontaining structural analogs of the marketed endothelin receptor A antagonist Ambrisentan, were ident
234                                              Endothelin receptor A antagonist BQ123 dramatically redu
235                          Conditional loss of endothelin receptor A in granulosa cells also decreased
236 heir spontaneous motion via the endothelin-1/endothelin receptor A pathway.
237 show that zebrafish harbouring a mutation in endothelin receptor aa (ednraa) form less cohesive shoal
238   In many studies, such as the Study with an Endothelin Receptor Antagonist in Pulmonary Arterial Hyp
239                                          The endothelin receptor antagonist is among the most effecti
240                                          The endothelin receptor antagonist macitentan has demonstrat
241 us epoprostenol were weaned off post-LT, and endothelin receptor antagonist or phosphodiesterase type
242                                              Endothelin receptor antagonists (ERA) and phosphodiester
243                                              Endothelin receptor antagonists have emerged as a novel
244                                              Endothelin receptor antagonists have revolutionized the
245  data support a potential role for selective endothelin receptor antagonists in protecting renal func
246                    Additionally, infusion of endothelin receptor antagonists into the bursa of wild-t
247 were receiving riociguat in combination with endothelin receptor antagonists or prostanoids, or both.
248 ials continue to explore new applications of endothelin receptor antagonists, particularly in treatme
249 erent classes of drugs are now available-ie, endothelin receptor antagonists, phosphodiesterase-5 inh
250 ts, which have been previously attributed to endothelin receptor antagonists, were more frequent in t
251 se biological effects that are unaffected by endothelin receptor antagonists.
252 terase type 5 inhibitors, sodium nitrite and endothelin receptor antagonists.
253                          ALK5 inhibition and endothelin receptor antagonization inhibited mesenchymal
254                             Animal models of endothelin receptor B (EdnrB) mutation reliably model hu
255                             We observed that endothelin receptor B [ET-B (gene name EDNRB)], the rece
256 lling through the G protein-coupled receptor endothelin receptor B and PKC epsilon, regulates the num
257  in the neural crest-conditional deletion of endothelin receptor B model of Hirschsprung-associated e
258 ts may constitute the mechanism of action of endothelin receptor blockers in DN.
259 scular endothelial nitric oxide synthase and endothelin receptor expression and impaired exercise tol
260 Furthermore, depletion of EDN1 or the use of endothelin receptor inhibitors bosentan and ambrisentan
261   In mice, podocyte-specific knockout of the endothelin receptor prevented the diabetes-induced incre
262                                          The endothelin receptor type A (EDNRA) signaling pathway is
263 2 activate two G protein-coupled receptors - endothelin receptor type A (ET(A)) and endothelin recept
264 ogenesis of BMSCs was attenuated by blocking endothelin receptor type A (ETAR) and/or endothelin rece
265 ors - endothelin receptor type A (ET(A)) and endothelin receptor type B (ET(B)) - with equal affinity
266                 These cells highly expressed endothelin receptor type B (ETB(R)) and Jagged1, a Notch
267                                          The endothelin receptor type B (ETBR) regulates water and el
268 ing endothelin receptor type A (ETAR) and/or endothelin receptor type B (ETBR).
269 otein endothelin 3 (EDN3), its receptor (the endothelin receptor type B [EDNRB]), and the transcripti
270 genome sequencing, we discovered that EDNRB (Endothelin receptor type B) is a candidate gene involved
271                                              Endothelin-receptor antagonists are in clinical use to t
272                Endothelin ligands (Edns) and endothelin receptors (Ednrs) are unique to vertebrates(3
273 of diabetes, include use of drugs that block endothelin receptors (eg, atrasentan) and non-steroidal
274                                              Endothelin receptors are also expressed on the human ecc
275 he endothelin axis and in particular the two endothelin receptors, ETA and ETB, are targets for thera
276 bofibrosis, which were prevented by blocking endothelin receptors.
277                                 We show that Endothelin signaling activates Mef2c expression in the n
278     These data suggest that OA-NO2 modulates endothelin signaling by increasing Nrf2-dependent expres
279 duplication and specialization of vertebrate Endothelin signaling coincided with the appearance of hi
280  ednr expression, we also analyzed all known Endothelin signaling components in the African clawed fr
281                To test the potential role of endothelin signaling diversification in the evolution of
282 nscriptional effectors directly activated by Endothelin signaling during neural crest development rem
283 amine in more detail the effect of OA-NO2 on endothelin signaling in human endothelial cells.
284 tream transcriptional target and effector of Endothelin signaling in the neural crest.
285 diate transcriptional effector and target of Endothelin signaling in the neural crest.
286                                              Endothelin signaling in turn induces expression of the r
287                        In jawed vertebrates, Endothelin signaling involves multiple functionally dist
288 r neural crest development, and dysregulated Endothelin signaling is associated with several neural c
289                                              Endothelin signaling is essential for neural crest devel
290                                              Endothelin signaling regulates several aspects of NCC de
291                                              Endothelin signaling via the activation of the endotheli
292        Additionally, we show that increasing endothelin signalling rescues this myelination defect ca
293            Here we define a pathway in which endothelin, signalling through the G protein-coupled rec
294 acrine and autocrine factors, especially the endothelin system, are regulated by clock genes.
295  FRET-based biosensors, we show that LPA and endothelin transiently activate Cdc42 through Gi, concur
296 veral studies reported a central role of the endothelin type A receptor (ETAR) in tumor progression l
297 es to angiotensin type 1 receptor (AT1R) and endothelin type A receptor (ETAR) is associated with all
298 s significantly increased by blockade of the endothelin type A receptor with ABT-627 (0.116 +/- 0.006
299 ge factor 6, angiotensin-II type 1 receptor, endothelin type A receptor, lamin B1, BPI fold-containin
300 scular endothelial nitric oxide synthase and endothelin was assessed in lung tissue to determine diff

 
Page Top